-
Jul 2, 2025 Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
-
May 25, 2025 Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
-
May 20, 2025 Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
-
May 13, 2025 Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
-
May 13, 2025 Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
-
May 13, 2025 Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
-
May 13, 2025 Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre
-
May 9, 2025 Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)( 2 ) NDA in the United States
-
May 7, 2025 Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain following ocular surgery
-
Feb 24, 2025 Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
-
Feb 5, 2025 Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride)
-
Feb 5, 2025 Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
-
Feb 3, 2025 Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch oxcarbazepine ER tablets in the United States
-
Aug 7, 2024 Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology
-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
-
May 15, 2024 Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States
-
Apr 2, 2024 Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.